- Main
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression
- Fores-Martos, Jaume;
- Cervera-Vidal, Raimundo;
- Sierra-Roca, Julia;
- Lozano-Asencio, Carlos;
- Fedele, Vita;
- Cornelissen, Sten;
- Edvarsen, Hege;
- Tadeo-Cervera, Irene;
- Eroles, Pilar;
- Lluch, Ana;
- Tabares-Seisdedos, Rafa;
- Falcó, Antonio;
- Van’t Veer, Laura J;
- Schmidt, Marjanka;
- Quigley, David A;
- Børresen-Dale, Anne-Lise;
- Kristensen, Vessela N;
- Balmain, Allan;
- Climent, Joan
- et al.
Abstract
Polymorphisms in the PER3 gene have been associated with several human disease phenotypes, including sleep disorders and cancer. In particular, the long allele of a variable number of tandem repeat (VNTR) polymorphism has been previously linked to an increased risk of breast cancer. Here we carried out a combined germline and somatic genetic analysis of the role of the PER3VNRT polymorphism in breast cancer. The combined data from 8284 individuals showed a non-significant trend towards increased breast cancer risk in the 5-repeat allele homozygous carriers (OR = 1.17, 95% CI: 0.97-1.42). We observed allelic imbalance at the PER3 locus in matched blood and tumor DNA samples, showing a significant retention of the long variant (risk) allele in tumor samples, and a preferential loss of the short repetition allele (p = 0.0005). Gene co-expression analysis in healthy and tumoral breast tissue samples uncovered significant associations between PER3 expression levels with those from genes which belong to several cancer-associated pathways. Finally, relapse-free survival (RFS) analysis showed that low expression levels of PER3 were linked to a significant lower RSF in luminal A (p = 3 × 10-12) but not in the rest of breast cancer subtypes.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-